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Abstract
Background: ASCL1 role in pancreatic endocrine tumourigenesis has not been established.
Recently it was suggested that ASCL1 negatively controls expression of the Wnt signalling
antagonist DKK1. Notch signalling regulates expression of TPH1, the rate limiting enzyme in the
biosyntesis of serotonin. Understanding the development and proliferation of pancreatic endocrine
tumours (PETs) is essential for the development of new therapies.
Methods: ASCL1 target genes in the pancreatic endocrine tumour cell line BON1 were identified
by RNA interference and microarray expression analysis. Protein expressions of selected target
genes in PETs were evaluated by immunohistochemistry.
Results: 158 annotated ASCL1 target genes were identified in BON1 cells, among them DKK1 and
TPH1 that were negatively regulated by ASCL1. An inverse relation of ASCL1 to DKK1 protein
expression was observed for 15 out of 22 tumours (68%). Nine tumours displayed low ASCL1/high
DKK1 and six tumours high ASCL1/low DKK1 expression. Remaining PETs showed high ASCL1/
high DKK1 (n = 4) or low ASCL1/low DKK1 (n = 3) expression. Nine of twelve analysed PETs
(75%) showed TPH1 expression with no relation to ASCL1.
Conclusion: A number of genes with potential importance for PET tumourigenesis have been
identified. ASCL1 negatively regulated the Wnt signalling antagonist DKK1,a n dTPH1 expression in
BON1 cells. In concordance with these findings DKK1 showed an inverse relation to ASCL1
expression in a subset of PETs, which may affect growth control by the Wnt signalling pathway.
Background
Pancreatic endocrine tumours (PETs) are derived from
the embryologic endoderm and accounts for 1-2% of
pancreatic cancer. The only currently curative therapy for
patients with PETs is surgical resection. PETs occur
sporadically or are familial in nature, caused by germ
line mutations in the Multiple endocrine neoplasia 1
(MEN1) or von Hippel-Lindau (VHL) tumour suppressor
genes. Understanding the molecular pathways that
control PET development and proliferation are essential
for possible development of novel therapies.
The basic helix loop helix (bHLH) transcription factor
Achaete-scute complex homolog 1 (Ascl1) has been
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Open Accessshown to play important regulatory roles in adrenal
medullary chromaffin cells [1], thyroid parafollicular
C-cells [2] and pulmonary endocrine cells [3]. Ascl1 is
tightly controlled by the Notch signalling pathway in the
developing pancreas and governs the exocrine versus
endocrine cell fate decision [4]. Forced Notch activation
expands the pool of undifferentiated precursor cells and
inhibits the initial emergence of endocrine cells and the
following exocrine differentiation [5,6], whereas disrup-
tion of Notch signalling results in precocious endocrine
differentiation [4]. The active form of Notch, NICD,
induces the expression of Hairy and enhancer of split 1
(HES1) which in turn antagonises the expression of
bHLH genes such as ASCL1, with subsequent inhibition
of progenitor cell differentiation [7].
We have recently reported that ASCL1 is invariably
expressed in PETs, and suggested that the observed lack
of nuclear HES1 might contribute to the expression of
ASCL1 in these tumours [8]. In lung cancer cells ASCL1
negatively regulates the expression of Dickkopf homo-
logue 1 (DKK1) [9], an antagonist of the Wnt/b-catenin
signalling pathway which is involved in the development
of the exocrine pancreas [10] and in pancreatic beta cell
proliferation [11]. Furthermore, overexpression of
NOTCH1 in the human pancreatic endocrine tumour
cell line BON1 leads to inhibition of ASCL1 expression,
induction of HES1, reduced levels of endocrine markers
such as synaptophysin, and also to major repression of
TPH1 [12], the rate limiting enzyme in serotonin
biosynthesis. Serotonin is together with other hormones
implicated to cause the carcinoid syndrome.
Here we report on ASCL1 target genes in BON1 cells
transfected with ASCL1 siRNA.Inaddition,therelationof
DKK1 and TPH1 protein expression to ASCL1 expression
is studied in sporadic and familial (MEN 1) PETs.
Methods
Cell culture
The polyclonal BON1 cell line (a kind gift from Dr. J. C.
Thompson, Department of Surgery, University of Texas
Medical Branch, USA) was grown in 1:1 mixture of F12K
(Invitrogen, Life Technologies, Carlsbad, USA) and
DMEM (SVA, Uppsala, Sweden) medium supplemented
with 5% foetal bovine serum. The cells were grown at
37°C in a humidified 5.0% CO2/air atmosphere. siRNA
transfections were performed at 80% confluence. The
BON1 cell line is one of few human pancreatic endocrine
tumour cell lines available [13].
Immunofluorescent microscopy
BON1 cells were seeded on glass cover slips and fixed in
3.7% formaldehyde in phosphate-buffered saline (PBS)
(Sigma Aldrich, St Louis, USA) for 30 min, and washed
with PBS. The cells were permeabilised in 0.2% Triton
X-100 (Sigma) in PBS for 5 min, washed again in PBS,
and incubated in 5% foetal bovine serum in PBS for 60
min at room temperature. Primary as well as secondary
antibodies were diluted in PBS containing 5% FBS. Cells
were incubated with anti-ASCL1 mouse antibody (BD
Biosciences, San Jose, USA) or anti-HES1 goat antibody
(Santa Cruz Biotechnology, Santa Cruz, USA) followed
by FITC-labelled secondary antibodies and TRITC-
labelled phalloidin with a washing step in between.
The cover slips were mounted on object slides by the use
of Vectashield with DAPI (Vector laboratories, Burlin-
game, USA). Cells were photographed by an Axiocam
HRm camera employing the Axiovision imaging software
using a 63× plan-apochromat objective and a Zeiss
Axioplan2 microscope (Carl Zeiss Inc., Oberkochen,
Germany).
siRNA transfection
The two siRNAs were pre-designed (Ambion, USA, ID
114405 and AM4635). 5′-CGCGUUAUAGUAACUCC-
CATT and 5′-UGGGAGUUACUAUAACGCGTG (siRNA/
A) and 5′-AGUACUGCUUACGAUACGGTT and 5′-TTU-
CAUGACGAAUGCUAUGCC (Control siRNA). Transfec-
tions were performed with 10-30 nmol siRNA in 12 well
plates (80 0000 cells/well) using the jetSI-ENDO
transfection reagent (Poly-Plus-Transfection SAS, Ill-
kirch, France) according to the manufacturer’sp r o t o c o l .
Samples were not pooled for downstream applications.
RNA isolation and cDNA synthesis
Cells were harvested 72 hours after transfection and total
RNA was extracted using TriZol Reagent (Invitrogen)
according to manufacturer’s instructions. The RNA
concentration and quality were assessed using the
Agilent Bioanalyser (Agilent Technologies, Palo Alto,
USA). The RNeasy Mini Kit (Qiagen, Holden, Germany)
was used to further purify the RNA samples. cDNA was
synthesised from 1 μgo ft o t a lR N Au s i n gt h eH i g h
Capacity cDNA Archive Kit (Applied Biosystems, Foster
City, USA) according to the manufacturer’s instructions.
Quantitative real-time PCR (qPCR)
Relative mRNA expression was determined by qPCR, and
compared to positive controls comprising lung carcinoid
cell lines H727 and H720 (CRL-5815 and CRL-5838,
L G CP r o m o c h e m ,M i d d l e s e x ,U K .D a t an o ts h o w n ) .
Commercially available primer and probe sets were used
and measured against standard curves generated from
dilution series of cDNA from cell lines H727, H720 and
BON1. The following primers/probe mixes were used:
ASCL1; Hs00269932_m1, TCF3; Hs01016249_m1,
DLL1; Hs 00194509_m1, SYP; Hs00300531_m1, TPH1;
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(Applied Biosystems). Reactions were performed and
analysed using an Applied Biosystems PRISM 7700
Sequence Detector. Standard cycling conditions were
used. Triplicate of each cDNA was used and each assay
was performed twice. The gene-specific signals were
normalised to expression of ACTB and PPIA endogenous
control genes (primer/probe mix 4333762F and
4333763T).
Western blotting
Protein extracts for Western blotting were prepared by
lysing the cells in RIPA buffer (Sigma-Aldrich) supple-
mented with complete protease inhibitor cocktail (Roche
Diagnostics, Basel, Switzerland). Protein sample from
each transfected well was separated in 12% SDS-
polyacrylamide gradient gels (BioRad, Hercules, USA),
transferred to PVDF membranes (GE Healthcare Europe
GmbH, Uppsala, Sweden) and blocked with SuperBlock
Blocking Buffer (Pierce Biotechnology, Rockford, USA)
overnight at 4°C. The membranes were incubated with
anti-ASCL1 monoclonal antibody (BD Biosciences) or
anti-a- Tubulin monoclonal antibody (Santa Cruz
Biotechnology) for 2 h. After briefly washing with PBS
containing 0.1% Tween 20, the filters were incubated
f o r1hw i t has e c o n d a r yg o a ta n t im o u s ea n t i b o d y
conjugated to horseradish peroxidase (1:5000 dilution).
The filters were washed and developed using the Super
Signal West femto kit (Pierce Biotechnology).
Microarray analysis
RNAs from successful siRNA transfection experiments
where used for microarray expression analysis. The
GeneChips, Human Genome U133 Plus 2.0 (Affymetrix,
Santa Clara, USA) was used for the analysis. 100
nanograms of total RNA from each sample were used
to prepare biotinylated fragmented cRNA using the two-
cycle cDNA synthesis part. GeneChip were hybridised for
16 hours in a 45°C incubator, rotated at 60 rpm
according to the GeneChip Expression Analysis Techni-
cal Manual (Rev. 5, Affymetrix). The arrays were washed
and stained using the Fluidics Station 450 and finally
scanned using the GeneChip Scanner 3000 7 G.
Bioinformatics
Differentially regulated genes were determined by
calculating the fold change between the nonspecific
siRNA transfected cell samples and the siRNA-ASCL1
transfected samples. Subsequent analysis of the gene
expression data was carried out in the freely available
statistical computing language R http://www.r-project.
org using packages available from the Bioconductor
project http://www.bioconductor.org. The raw data was
normalised using the robust multi-array average (RMA)
[14] background-adjusted, normalized and log-trans-
formed summarised values as first suggested by Li and
Wong in 2001 [15]. In order to search for the
differentially expressed genes between the samples
from the different groups an empirical Bayes moderated
t test was then applied [16], using the ‘limma’ package
[17]. To address the problem with multiple testing, the
p-values were adjusted according to Benjamini and
Hochberg [18]. We selected as significant only probe
sets with an adjusted p- v a l u e<0 . 0 1a n da na b s
(log2ratio) equal to or larger than1 (which corresponds
to a two-fold change in expression) to investigate further.
Tissue specimens
Pancreatic endocrine tumour specimens were obtained
from biobanks at the Department of Endocrine Oncol-
ogy, the Department of Surgery, and the Department of
Pathology at the Uppsala University Hospital. Frozen or
paraffin embedded tissues were used. Tumours were
initially frozen in liquid nitrogen and stored at −80°C
until analysis. Inclusions were based on the availability
of operative tissue specimens or biopsy material.
Altogether two gastrinomas, two glucagonomas (one
liver metastasis), five insulinomas and 14 non-function-
ing tumours were investigated. The mean age at
diagnosis was 48 years (range 19-86). Seven tumours
were from MEN 1 patients. The tumours were classified
according to the WHO classification of endocrine
neoplasms. For comparison, eight specimens of macro-
scopically determined non-tumourous pancreas adjacent
to a pancreatic endocrine tumour were assessed by
immunohistochemistry.
Immunohistochemistry
Twenty-two PETs were immunostained for DKK1.
Frozen, acetone-fixed sections (6 μm) were incubated
with an anti-DKK1 rabbit polyclonal antibody (SC-
25516, Santa Cruz Biotechnology) diluted in PBS with
1% BSA. The reaction product was revealed using a
biotinylated secondary antibody, Vectastain Elite ABC,
(Vector) and the chromogen 3-amino-9-ethylcarbazol
and 0.02% hydrogen peroxide as a substrate. Sections
were counterstained with Mayer’sh a e m a t o x y l i na n d
mounted. Twelve paraffin embedded PET specimens
were immunostained for TPH1. The rehydrated sections
were heat-retrieved and incubated with an anti-TPH1
mouse antibody (Sigma Aldrich). The reaction product
was revealed using the EnVision system -HPR (DakoCy-
tomation, Copenhagen, Denmark), and DAB as the
chromogen. Sections were counterstained with Mayer’s
haematoxylin and mounted. Each PET specimen and
non-tumourous pancreatic specimens were evaluated
independently by the authors and graded as low, high
or heterogeneous (i.e. areas of both low and high
BMC Cancer 2009, 9:321 http://www.biomedcentral.com/1471-2407/9/321
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ASCL1 has been published previously [8] and was
graded as negative (−), weak (+), moderate (++), or
strong (+++). In the present study we denoted strong
(+++) staining in the cytoplasm as High and weak or
moderate (+/++) as Low. Sections were photographed by
an AxioCam MR camera employing the Axiovision
imaging software using a LD A-plan 20×/40× 0.30 Ph1
objectives and a Zeiss Axiovert 40 microscope (Carl
Zeiss Inc.).
Statistical analysis
Unpaired t test was used for calculations regarding qPCR
expression. A p-value below 0.05 was considered
significant.
Ethical approval
Permission for this study was obtained from the Uppsala
Ethical Committee, Sweden. Informed consent was
gathered from all patients.
Results
Expression profiling in the pancreatic endocrine
tumour cell line BON1
RNA interference and microarray expression analysis
were employed in order to identify ASCL1 target genes in
BON1 cells. A specific siRNA to ASCL1 (ASCL1 siRNA/A)
and one non-specific Control siRNA were transfected to
BON1 cells. These cells are notoriously difficult to
transfect and 30 nmol of siRNA was found to be
optimal. ASCL1 siRNA/A was found to significantly
(p < 0.0001) reduce ASCL1 mRNA expression compared
to Control siRNA (Figure 1A). Importantly, ASCL1
protein expression was similarly reduced (Figure 1B).
In order to further validate the experimental system for
microarray expression analysis, the effects of reduced
ASCL1 expression by RNAi was evaluated on the known
or putative ASCL1 target genes Delta 1 (DLL1)a n d
Synaptophysin (SYP). ASCL1 is known to bind to the
DLL1 promoter and synergistically activate transcription
together with Pou3f3 and Pou3f4 [19,20]. Reduced
expression of ASCL1 negatively affects SYP expression
i nS C L Cc e l l sa sw e l la si np u l m o n a r ye n d o c r i n ec e l l so f
Ascl1 double null mice [3]. As a putative negative control
we also assessed expression of the transcription factor
TCF3 (E12/E47); a recognised dimerisation partner of
ASCL1 that is required for transcription activation of
ASCL1 target genes [21,22]. The results showed that
siRNA/A to ASCL1 significantly reduced DLL1 (p =
0.001) and SYP (p = 0.01) expression, while expression
of TCF3 was unaffected (Figures 2A-C).
S i n c ew eh a v eo b s e r v e dl a c ko fn u c l e a rH E S 1i nP E T s[ 8 ] ,
protein expression in BON1 cells was investigated by
fluorescent immunostaining. ASCL1 and HES1 were
clearly expressed in BON1 cells, with prominent nuclear
association (Figures 3 and 4).
Six validated RNA samples from transfections with
ASCL1 siRNA/A and Control siRNA were selected for
microarray expression analysis employing the Human
Genome U133 Plus 2.0 GeneChip. A total of 433
transcripts showed at least a two-fold difference in
expression in BON1 cells transfected with ASCL1 siRNA
compared to Control siRNA. Among annotated genes, 46
showed increased- and 112 reduced expression (Table 1;
Table 2). As anticipated, ASCL1 expression was decreased
(Table 2). Expression of both DKK1 and TPH1 were
f o u n dt ob ei n c r e a s e di nASCL1 siRNA transfected cells
(Table 1; Figure 5). Thus, ASCL1 negatively regulates
DKK1 and TPH1 in BON1 pancreatic endocrine tumour
Figure 1
(A) Relative expression of ASCL1 in siRNA-
transfected BON1 cells as determined by qPCR.
Expression levels were normalised to ACTB and PPIA
with similar results. Data are presented as mean ± SEM of
analysis in triplicates. * p < 0.05. (B) Western blotting
analysis for ASCL1. Protein extracts from siRNA-transfected
B O N 1c e l l sa si n d i c a t e d .
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MYCN and RET), those involved in the integrin system
(NRXN3, LAMA4 and SMOCK2), participating in apop-
tosis (PDCD6, CFLAR and CCAR1), as well as genes
known to be involved in the Notch, Wnt, NFb,T G F b
and MAP kinas signalling pathways. Many of the ASCL1
targets represent potential oncogenes and tumour
suppressor genes.
Gene ontology (GO) were applied to identify the
functional significance of all (n = 433) differentially
expressed transcripts with known function(s) http://
www.geneontology.org. Each differentially expressed
transcript was placed in functional GO categories and
over-represented categories are shown. The enrichment
of the GO data was narrowed down to broad GO terms.
The division was based on biological process, molecular
function, and cellular components. The most over-
represented GO biological process categories, according
to number of involved transcripts, related to regulation
of a biological or cellular processes, development,
metabolic processes or transcription and regulation of
transcription. For molecular function, most over-repre-
sented categories were binding activity (receptor, DNA or
nucleic acid) and transcription regulation (cofactor or
binding activity). For cellular components, the most
over-represented category was transcripts involved in
cellular junctions (Table 3).
Inverse expression of ASCL1 and DKK1 in the majority
of investigated PETs
Expression of DKK1 was evaluated by immunohisto-
chemistry in 22 out of the 23 analysed PETs (Figure 6;
T a b l e4 ) .I n v e r s er e l a t i o no fA S C L 1[ 8 ]t oD K K 1
expression was observed for 15 out of 22 tumours
(68%). Of these, nine tumours displayed low ASCL1/
high DKK1 and six tumours high ASCL1/low DKK1
expression. Thus, ASCL1 is likely to negatively regulate
DKK1 transcription in these tumours, as has been shown
to occur in A549 lung cancer cells [9]. The remaining
PETs showed high ASCL1/high DKK1 (n = 4) or low
ASCL1/low DKK1 (n = 3) expression. No relations of
ASCL1/DKK1 expression to tumour syndrome, MEN 1,
or WHO classification were observed.
TPH1 displays heterogeneous expression with no relation
to ASCL1 in PETs
T h ea m o u n to fi m m u n o r e a c t i v i t yv a r i e df o rT P H 1 .N i n e
out of the twelve analysed PETs (75%) showed a
heterogeneous expression pattern (Figure 6F, Table 4).
High expression was seen in two tumours and low
expression in one. Tumours with high or heterogeneous
expression showed a somewhat lower TPH1 expression
than control non-tumourous pancreatic tissue. No
relations of ASCL1 to TPH1 expression or to clinical
characteristics were observed.
Discussion
This study showed altogether 433 target transcripts (158
annotated genes) in the human pancreatic endocrine
tumour cell line BON1 that directly or indirectly were
regulated by ASCL1, among them several putative
oncogenes and suppressor genes. ASCL1 was found to
negatively regulate DKK1 and TPH1 expression in BON1
cells. This may suggest that Notch1 signalling pathway
regulatory factor(s) other than ASCL1 is involved in the
reduced expression of TPH1 observed in Notch1 over-
expressing BON cells [12]. In order to investigate if this
relation between ASCL1, DKK1 and TPH1 in vitro might
be of relevance in vivo, we analysed their protein
expression in PETs. An inverse relation of ASCL1 to
DKK1 expression was observed in 68% of the analysed
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Figure 2
Relative expression of SYP, DLL1,a n dTCF3 in siRNA-
transfected BON1 cells as determined by qPCR.
Expression levels were normalised to ACTB and PPIA with
similar results. Data are presented as mean ± SEM of analysis
in triplicates. * p < 0.05.
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Figure 3
Fluorescent immunostaining of ASCL1 in BON1 cells. Cells were visualised by TRITC-labeled phalloidin (blue)
and DAPI (red). Primary antibodies to ASCL1 were detected by FITC-labelled secondary antibodies (green).
Yellow, indicates co-localisation (merged).
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Figure 4
Fluorescent immunostaining of HES1 in BON1 cells. Cells were visualised by TRITC-labeled phalloidin (blue) and
DAPI (red). Primary antibodies to HES1 were detected by FITC-labelled secondary antibodies (green). Yellow, indicates
co-localisation (merged).
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and TPH1 expression levels was found.
ASCL1 has been found to repress DKK1 transcription, a
negative regulator of the Wnt signalling pathway in lung
cancer cells, and is also the first transcriptional repressor
identified for DKK1. The regulation is meditated by
histone deacetylation and repressive lysine 27 trimetyla-
tion in the promoter region of DKK1 [9]. Moreover,
downregulation of DKK1 has been associated with
colorectal- and breast cancer (23, 24). On the other
hand, DKK1 has also been identified as a potential
prognostic and diagnostic marker for cohorts of breast
cancer patients with poor prognosis [23] and increased
circulating levels of DKK1 has been associated with the
presence of bone metastases in patients with breast
cancer [25] We note that 13 out of the 22 analysed PETs
prominently expressed DKK1.
Wnt/b-catenin signalling is negatively regulated by DKK1
by inhibition of the complex formation between Wnts
and its receptors, LRP5/6. It has been advocated that
ASCL1 expression may favour cancer cell growth through
repression of DKK1 with the consequential aberrant
activation of the Wnt/b-catenin signalling pathway [9].
This may also apply to a subset of PETs as a total of 9 out
of 22 PETs displayed low DKK1 immunoreactivity.
ASCL1 may have a coordinating role in production of
serotonin by transcriptional regulation of TPH1 and could
thereby be involved in causing the carcinoid syndrome in
patients with PET [12]. Our results from the microarray
expression analysis in BON1 cells suggested that TPH1
might constitute a ASCL1 target gene in BON1 cells.
However, an obvious relation between ASCL1 and TPH1
proteinexpressionlevelswerenotfound,andTPH1showed
a heterogeneous pattern of immunoreactivity in PETs.
Table 1: Annotated genes with increased expression in BON1 cells transfected with siRNA to ASCL1
Gene Symbol Gene Name Location Ratio adj p Value
RBM24 RNA binding motif protein 24 6p22.3 4,708 0,0000391
HAS2 hyaluronan synthase 2 8q24.12 3,279 0,0002805
MYCN v-myc myelocytomatosis viral related oncogene, 2p24.1 2,777 0,0000305
C13orf15 chromosome 13 open reading frame 15 13q14.11 2,594 0,0000701
APCDD1 adenomatosis polyposis coli down-regulated 1 18p11.22 2,569 0,0000305
LGR5 leucine-rich repeat-containing G protein-coupled receptor 5 12q22-q23 2,540 0,0003188
DKK1* dickkopf homolog 1 (Xenopus laevis) 10q11.2 2,349 0,0000155
TPH1* Tryptophan hydroxylase 1 11p15.3-p14 2,325 0,0002805
ID4 Inhibitor of DNA binding 4 6p22-p21 2,317 0,0001962
PVRL3 poliovirus receptor-related 3 3q13 2,295 0,0000949
TIMP2 TIMP metallopeptidase inhibitor 2 17q25 2,286 0,0000200
ASAM adipocyte-specific adhesion molecule 11q24.1 2,254 0,0002763
SPOCK1 sparc/osteonectin, cwcv and kazal-like domains 5q31 2,251 0,0000796
NRXN3 neurexin 3 14q31 2,246 0,0002025
KL klotho 13q12 2,240 0,0000150
GPD2 glycerol-3-phosphate dehydrogenase 2 (mitochondrial) 2q24.1 2,238 0,0000155
CLIC5 chloride intracellular channel 5 6p21.1-p12.1 2,235 0,0000313
EMG1 EMG1 nucleolar protein homolog (S. cerevisiae) 12p13 2,230 0,0000489
DRD1IP dopamine receptor D1 interacting protein 10q26.3 2,219 0,0001121
CXCR7 chemokine (C-X-C motif) receptor 7 2q37.3 2,216 0,0000862
STOML3 stomatin (EPB72)-like 3 13q13.3 2,196 0,0003867
SI sucrase-isomaltase (alpha-glucosidase) 3q25.2-q26.2 2,181 0,0000701
FGF13 fibroblast growth factor 13 Xq26.3 2,178 0,0000288
CHM choroideremia (Rab escort protein 1) Xq21.2 2,150 0,0000396
GLCE glucuronic acid epimerase 15q23 2,144 0,0000561
DC2 DC2 protein 4q25 2,143 0,0000181
SMS spermine synthase Xp22.1 2,113 0,0003207
GPD2 glycerol-3-phosphate dehydrogenase 2 (mitochondrial) 2q24.1 2,095 0,0000586
LOC283454 hypothetical protein LOC283454 12q24.23 2,095 0,0000465
CXorf57 chromosome X open reading frame 57 Xq22.3 2,094 0,0003208
PTGES3 prostaglandin E synthase 3 (cytosolic) 12. 2,091 0,0000430
HS2ST1 heparan sulfate 2-O-sulfotransferase 1 1p31.1-p22.1 2,080 0,0001750
EMP1 epithelial membrane protein 1 12p12.3 2,066 0,0000357
EBAG9 estrogen receptor binding site associated, antigen, 9 8q23 2,058 0,0000919
VPS37B vacuolar protein sorting 37 homolog B (S. cerevisiae) 12q24.31 2,049 0,0000640
NOV nephroblastoma overexpressed gene 8q24.1 2,001 0,0000746
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Gene Symbol Gene Name Location Ratio adj P Value
FAM87A family with sequence similarity 87, member A 8p23.3 0,221 0,0000104
DKFZP761C1711 Hypothetical protein DKFZp761C1711 0,246 0,0000258
GABRA1 gamma-aminobutyric acid (GABA) A receptor, alpha 1 5q34-q35 0,260 0,0000172
GUSBP1 glucuronidase, beta pseudogene 1 7q21.11 0,277 0,0000104
TncRNA trophoblast-derived noncoding RNA 11q13.1 0,284 0,0000104
LOC728411 Similar to Beta-glucuronidase precursor 5. 0,296 0,0000104
TTLL5 tubulin tyrosine ligase-like family, member 5 17q21.32 0,328 0,0001110
EBF1 Early B-cell factor 1 5q34 0,333 0,0000112
VPS13C Vacuolar protein sorting 13 homolog C (S. cerevisiae) 15q21.3 0,341 0,0000150
RNF12 Ring finger protein 12 Xq13-q21 0,342 0,0000283
ASCL1* achaete-scute complex homolog 1 (Drosophila) 12q22-q23 0,351 0,0000162
SORBS2 sorbin and SH3 domain containing 2 4q35.1 0,353 0,0000161
ERBB4 v-erb-a erythroblastic leukemia viral oncogene homolog 4 2q33.3-q34 0,359 0,0001092
FLJ38379 hypothetical protein FLJ38379 2q37.3 0,360 0,0001245
TCF12 Transcription factor 12 15q21 0,365 0,0000283
PGM5 phosphoglucomutase 5 9q13 0,365 0,0000499
RIT1 Ras-like without CAAX 1 1q22 0,366 0,0000150
ZCCHC7 Zinc finger, CCHC domain containing 7 9p13.2 0,371 0,0001730
LOC730168 hypothetical protein LOC730168///LOC732289 3q26.32 0,374 0,0000625
CFLAR CASP8 and FADD-like apoptosis regulator 2q33-q34 0,374 0,0001083
C11orf80 chromosome 11 open reading frame 80 11q 0,375 0,0000579
CCAR1 Cell division cycle and apoptosis regulator 1 10q21.3 0,375 0,0000796
FAM81B family with sequence similarity 81, member B 5q15 0,382 0,0000599
FLJ25770 hypothetical protein FLJ25770 4q21.1 0,383 0,0000181
LOC730390 SMA4///similar to SMA4 5q13 0,385 0,0000159
ZFAND6 Zinc finger, AN1-type domain 6 15q25.1 0,387 0,0000246
LOC728555 hypothetical protein LOC728555///LOC730391 5q13.2 0,388 0,0000151
GRAMD3 GRAM domain containing 3 5q23.2 0,394 0,0000136
CBFA2T2 core-binding factor, runt domain, alpha subunit 2 20q11 0,394 0,0000181
ZNF638 Zinc finger protein 638 2p13.2-p13.1 0,396 0,0019556
LOC728678 hypothetical protein LOC728678///LOC731914 3p22.3 0,397 0,0000150
CLCN5 chloride channel 5 Xp11.23-p11.22 0,398 0,0000170
ANXA13 annexin A13 8q24.13 0,412 0,0000181
RP11-506K6.3 Hypothetical LOC389362 6p25.2 0,415 0,0002632
FLJ23556 hypothetical protein FLJ23556 10q25.2 0,417 0,0000788
PFAAP5 Phosphonoformate immuno-associated protein 5 13q13.1 0,417 0,0000150
PCDHGA4 protocadherin gamma subfamily A, 4 5q31 0,419 0,0000274
LOC145474 hypothetical protein LOC145474 14q24.1 0,421 0,0003892
IFIT1 interferon-induced protein 10q25-q26 0,421 0,0006010
DKFZp547E087 hypothetical gene LOC283846 18p11.21 0,424 0,0000586
TXNIP thioredoxin interacting protein 1q21.1 0,427 0,0000305
CDC14B CDC14 cell division cycle 14 homolog B 9q22.33 0,432 0,0000885
RUFY2 RUN and FYVE domain containing 2 10q21.3 0,432 0,0001373
KLHL28 Kelch-like 28 (Drosophila) 14q21.3 0,435 0,0002095
MBNL2 Muscleblind-like 2 (Drosophila) 13q32.1 0,436 0,0000246
LOC730496 hypothetical protein LOC730496 1. 0,436 0,0000150
PRKAA1 protein kinase, AMP-activated, alpha 1 catalytic subunit 5p12 0,436 0,0002228
NR5A2 nuclear receptor subfamily 5, group A, member 2 1q32.1 0,438 0,0003777
LOC388743 similar to calpain 8 1q41 0,440 0,0000284
PTPN13 Protein tyrosine phosphatase, non-receptor type 13 4q21.3 0,441 0,0011559
RASAL2 RAS protein activator like 2 1q24 0,442 0,0003715
LOC730258 neuroblastoma breakpoint family, member 1, 3, 8, 10 1q21.1 0,443 0,0000150
ZNF518 Zinc finger protein 518 10q23.33 0,445 0,0002293
SCNN1A sodium channel, nonvoltage-gated 1 alpha 12p13 0,445 0,0000176
CTAGE5 CTAGE family, member 5 14q13.3 0,446 0,0000617
LOC440895 similar to LIM and senescent cell antigen-like domains 3 2q13 0,446 0,0003164
PELI1 Pellino homolog 1 (Drosophila) 2p13.3 0,449 0,0001121
FAM98A Family with sequence similarity 98, member A 2p22.3 0,449 0,0000499
BRWD2 bromodomain and WD repeat domain containing 2 10q26 0,450 0,0000602
C20orf74 chromosome 20 open reading frame 74 20p11.22 0,450 0,0000926
MALAT1 metastasis associated lung adenocarcinoma transcript 1 2p16.3 0,452 0,0001060
RTN4 reticulon 4 2p16.3 0,453 0,0004446
LOC654342 Similar to lymphocyte-specific protein 1 2p11.1 0,454 0,0000284
CYorf15B chromosome Y open reading frame 15B Yq11.222 0,455 0,0001245
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focused on the involvement of Notch signalling factors
like ASCL1 in neural stem cell differentiation. Even
though pancreatic endocrine cells have an endodermal
origin they also share several molecular features with
neurons. Like neurons in the central nervous system,
differentiating endocrine cells in the pancreas appear in a
scattered fashion within a field of progenitor cells. The
different cell types are generated by lateral inhibition
through Notch signalling [4]. With this in mind it is not
surprising that the results from the GO analysis suggest
that ASCL1 target genes participate in cellular differ-
entiation, migration and localisation of cells also in
pancreatic endocrine cells.
Conclusion
The present findings support the notion that ASCL1 is
involved in pancreatic endocrine tumourigenesis, where
aberrant expression of DKK1 may play additional
important roles. ASCL1 also directly or indirectly
regulates expression of several putative oncogenes and
Table 2: Annotated genes with decreased expression in BON1 cells transfected with siRNA to ASCL1 (Continued)
SMOC2 SPARC related modular calcium binding 2 6q27 0,456 0,0002821
CAPN2 calpain 2, (m/II) large subunit 1q41-q42 0,457 0,0000460
HEL308 DNA helicase HEL308 4q21.23 0,459 0,0006091
PDCD6 Programmed cell death 6 5pter-p15.2 0,459 0,0000722
LOC285147 hypothetical protein LOC285147 2p25.2 0,460 0,0001063
TFF3 trefoil factor 3 (intestinal) 21q22.3 0,460 0,0010306
RIMBP2 RIMS binding protein 2 12q24.33 0,461 0,0000520
C10orf93 chromosome 10 open reading frame 93 10q26.3 0,462 0,0000950
SUCNR1 succinate receptor 1 3q24-q25.1 0,462 0,0000603
LOC151878 hypothetical protein LOC151878 3p14.3 0,463 0,0003715
LRRFIP1 Leucine rich repeat (in FLII) interacting protein 1 2q37.3 0,465 0,0000339
ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 10q26.3 0,465 0,0003076
GART Phosphoribosylglycinamide, phosphoribosylaminoimidazole 21q22.11 0,466 0,0003142
PLGLB1/2 plasminogen-like B2///plasminogen-like B1 2p11-q11 0,467 0,0007445
RET ret proto-oncogene 10q11.2 0,467 0,0000247
POLQ polymerase (DNA directed), theta 3q13.33 0,467 0,0002632
KIAA1632 KIAA1632 18q12.3-q21.1 0,468 0,0004005
ADAM28 ADAM metallopeptidase domain 28 8p21.2 0,469 0,0000950
MSI2 Musashi homolog 2 (Drosophila) 17q22 0,469 0,0000344
JMJD1C jumonji domain containing 1C 10q21.2-q21.3 0,470 0,0001013
DST dystonin 6p12.1 0,473 0,0001509
NT5E 5'-nucleotidase, ecto (CD73) 6q14-q21 0,474 0,0000288
LYST lysosomal trafficking regulator 1q42.1-q42.2 0,475 0,0001027
SYK Spleen tyrosine kinase 9q22 0,476 0,0003933
DLG1 Discs, large homolog 1 (Drosophila) 3q29 0,476 0,0006683
RASSF6 Ras association (RalGDS/AF-6) domain family 6 4q13.3 0,476 0,0006133
TRA2A transformer-2 alpha 1p36.11 0,478 0,0000701
UBE2D3 ubiquitin-conjugating enzyme E2D 3 4q24 0,479 0,0002430
TMEM46 transmembrane protein 46 13q12.13 0,480 0,0000248
INADL InaD-like (Drosophila) 1p31.3 0,480 0,0002693
TTC30A tetratricopeptide repeat domain 30A 2q31.2 0,484 0,0003577
SNAP25 Synaptosomal-associated protein, 25 kDa 20p12-p11.2 0,484 0,0000189
PRO2852 hypothetical protein PRO2852 9. 0,485 0,0000460
MLLT3 myeloid/lymphoid or mixed-lineage leukemia 9p22 0,486 0,0004334
RBM6 RNA binding motif protein 6 3p21.3 0,488 0,0002432
PPP2R5C protein phosphatase 2, regulatory subunit B', 14q32 0,488 0,0000241
GOPC Golgi associated PDZ and coiled-coil motif containing 6q21 0,489 0,0006453
LAMA4 laminin, alpha 4 6q21 0,489 0,0001402
SFRS15 splicing factor, arginine/serine-rich 15 21q22.1 0,490 0,0000344
KIF13A kinesin family member 13A 6p23 0,491 0,0001644
CLASP2 cytoplasmic linker associated protein 2 3p22.3 0,493 0,0004942
MMAA Methylmalonic aciduria (cobalamin deficiency) cblA type 4q31.22 0,493 0,0002644
C1orf192 chromosome 1 open reading frame 192 1q23.3 0,494 0,0006859
hCG_2003663 hCG2003663 9q22.32 0,494 0,0006724
SMOC1 SPARC related modular calcium binding 1 14q24.2 0,494 0,0001073
REV3L REV3-like, catalytic subunit of DNA polymerase zeta 6q21 0,496 0,0001092
SMAD1 SMAD family member 1 4q31 0,496 0,0004345
TWF1 twinfilin, actin-binding protein, homolog 1 (Drosophila) 12q12 0,497 0,0001687
FBXO9 F-box protein 9 6p12.3-p11.2 0,497 0,0000391
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(page number not for citation purposes)tumours suppressor genes in pancreatic endocrine
tumour cells that may contribute to the neoplastic
process.
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Figure 6
Immunohistochemical analysis of ASCL1, DKK1, and
TPH1 in pancreatic endocrine tumours and non-
tumourous pancreatic specimen. Pancreatic islets are
indicated by arrows. Representative immunostainings are
shown. (A) High ASCL1 expression in tumour no. 5 (×200),
(B) Low ASCL1 expression in tumour no. 23 (×200), (C)
Low DKK1 expression in tumour no. 5 (×200), (D) High
DKK1 expression in tumour no. 10 (×200), (E) DKK1
expression in non-tumourous pancreas (×200), (F)
heterogeneous TPH1 expression in tumour no. 10 (×200),
(G) TPH1 expression in non-tumourous pancreas (×400).
Table 3: Functional GO categories
Systems Categorys No. of
genes or
transcripts
Biological processes
Regulation of biological or cellular process 342
Development regulation/cellular 292
Cellular metabolic process 189
Transcription and regulation of transcription 144
Biological/cellular adhesion 68
Regulation of nucleo -base -side, -tide and
nucleic acid metabolic process
62
Regulation of gene expression 56
Cell differentiation 44
L o c o m o t i o n ,c e l l u l a ro rr e g u l a t i o no f 2 9
Cellular migration/localisation 26
Phosphorylation 20
Neurogenes 19
Protein amino acid phosphorylation 17
Carbohydrate biosynthetic process 5
Integrin-mediated signalling pathway 5
Molecular functions
Binding activity, receptor, DNA, nucleic acid 305
Transcription regulation/cofactor or binding
activity
67
Kinase activity 54
Phosphotransferase activity 49
Ligase activity ubiquitin/amino acid/small
conjugating protein
24
Ligase activity 20
Enzyme activator activity 13
Transmembrane receptor protein kinase activity 11
Cellular components
Cell junction 14
Intercellular junction 8
Basement membrane 5
Functional categories are based on GO annotation. Note that in GO
function hierarchy, some genes/transcripts belong to multiple categories.
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Figure 5
Relative expression of DKK1and TPH1 in siRNA-
transfected BON1 cells as determined by qPCR.
Data are presented as mean ± SEM of analysis in triplicates.
* p <0 . 0 5 .
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